WASHINGTON — Voters in several battleground states overwhelmingly support several of President Trump’s recent proposals to drastically cut drug prices. But they’re markedly less enthusiastic about his plan to end drug rebates, according to a new poll shared first with STAT.

A full 87% of the voters surveyed support Trump’s idea to force drug companies to sell their drugs in the U.S. at the prices they offer in other similar countries, and 82% support his efforts to allow people to import drugs from Canada, according to the poll of 2,000 people in Arizona, Florida, Michigan, Pennsylvania, and Wisconsin. It was conducted by McLaughlin & Associates and sponsored by the insurance lobby, America’s Health Insurance Plans, which supports both of those policy changes.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • What a joke of a poll to throw into the election hyperbole. Some of us have had to purchase drugs under high deductible health plans for a long time, and some of us even paid attention to what happened with Ohio Medicaid in 2018. It’s just a matter of time.

  • Let me get this straight. A group opposed to rebate reform conducts a survey that finds opposition to rebate reform–and the detailed survey questions and methodology are top secret? Yes, that sounds like totally credible research …

    • Lol, so true Adam…. Typical PCMA response , everything is a big secret. I wonder how much money the PBM’s pocketed last year on drug rebates .. oh yea this too is top secret !!! What a bunch of crap!!

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy